Skip over navigation
Banner
Directory
Directory Search
Jobs
Job Search Post a Job
Patient
Patient Resources Drug Development
History
Genealogy
Industry
 Directory
 WA History
Quick Links
 Directory
 Job Search
 History
 Advertising
 
Events
 

EquipNet Auction: Major Lab Site Closures, Assets from Cyclerion and Proteostasis, March 25


Washington Life Science Industry Directory

Lundbeck Seattle BioPharmaceuticals Lundbeck -- tirelessly dedicated to restoring brain health.

Target your advertising by state, region or nationwide for the same low rate

Banner Advertising | Event Advertising

Nativis Inc.


Nativis Inc.
24 Roy Street, Suite 437
Seattle, WA 98109
Nativis Inc.
 
Phone: (206) 708-2288
Year Established:  2002
Main Contact: Michael Mischke-ReedsMischke-Reeds, Senior VP, Business Development
 
Other Contacts:  Michael K. Matysik, MBA, CFO
Donna Morgan Murray, PhD, CRO
Deborah Sheffield, MSc, Head of Quality Systems, Clinical and Regulatory Affairs
Xavier A. Figueroa, Ph.D., Director, Pre-clinical Development
Steven E. Pope, Senior VP, General Counsel
Kenneth Ferguson, Ph.D., CSO
Eric Peterson, Director of Development & Manufacturing
Chris E. Rivera, President & CEO
 
Company Description
Nativis, formerly WavBank, is a clinical-stage bio-electronics company. Nativis has invented and patented a groundbreaking technology that utilizes precisely targeted, ultra-low radio frequency energy (ulRFE) to specifically regulate metabolic pathways on the molecular and genetic levels – without chemicals, radiation or drugs – delivered via a simple-to-use non-invasive device called Nativis Voyager®. The company’s goal is to transform disease treatment on a global scale with ulRFE that can potentially be applied to a wide range of conditions and other health-related needs (including agriculture, bio-fuels and veterinary medicine, to name a few). Nativis’ initial focus is on the treatment of patients with brain cancer (initially, recurrent glioblastoma), who are not well served by conventional standard of care therapies, which often result in poor outcomes and devastating side effects. Additional pre-clinical work is being completed for melanoma, lung cancer, liver cancer, inflammatory disease and chronic pain.


Main Industry Directory

 
Email thie page to a friend. Email This Page
to a Friend
Print this page. Print This
Page
© 1997 - 2021 Info.Resource, Inc. All rights reserved.
Privacy Policy . Cookie Policy . Terms of Use . About . Advertising

WashingtonLifeScience.com is owned and published by Info.Resource, Inc.